Back
Apellis Pharmaceuticals Quote, Financials, Valuation and Earnings

Serious profits in months with teeny tiny gains?
Check out the details here.
Buy
80
APLS
Apellis Pharmaceuticals
Last Price:
64.85
Seasonality Move:
20.51%
7 Day Trial
ALL ACCESS PASS
$
7

Wall Street Insider Makes Prediction about Hot A.I. Stock
Learn more here.Apellis Pharmaceuticals Price Quote
$64.85
-0.01 (1.5%)
(Updated: December 6, 2023 at 4:48 AM ET)
Apellis Pharmaceuticals Key Stats
Buy
80
Apellis Pharmaceuticals (APLS)
is a Buy
Day range:
$64.13 - $66.30
52-week range:
$19.83 - $94.75
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
27.58
P/B ratio:
33.09%
Volume:
2.5M
Avg. volume:
2M
1-year change:
31.35%
Market cap:
$7.7B
Revenue:
$75.4M
EPS:
$-5.25
How Much Does Apellis Pharmaceuticals Make?
-
How Much Are Apellis Pharmaceuticals's Sales Annually?
APLS Revenues are $75.4M -
How Much Profit Does Apellis Pharmaceuticals's Make A Year?
APLS net income is -$652.2M
Is Apellis Pharmaceuticals Growing As A Company?
-
What Is Apellis Pharmaceuticals's Growth Rate Quarterly?
Quarterly YoY revenue growth is 4.01% -
What Is Apellis Pharmaceuticals's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Apellis Pharmaceuticals Stock Price Performance
-
Did Apellis Pharmaceuticals Stock Go Up Last Month?
Apellis Pharmaceuticals share price went up by 38.5% last month -
Did APLS's Share Price Rise Over The Last Year?
APLS share price rose by 31.35% over the past 1 year
What Is Apellis Pharmaceuticals 52-Week High & Low?
-
What Is Apellis Pharmaceuticals’s 52-Week High Share Price?
Apellis Pharmaceuticals has traded as high as $94.75 over the past 52 weeks -
What Is Apellis Pharmaceuticals’s 52-Week Low Share Price?
Apellis Pharmaceuticals has traded as low as $19.83 over the past 52 weeks
Apellis Pharmaceuticals Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Apellis Pharmaceuticals?
-
How Much Debt Does Apellis Pharmaceuticals Have?
Total long term debt quarterly is $93M -
How Much Cash Does Apellis Pharmaceuticals Have?
Cash and short term investments quarterly total is $452.4M -
What Is Apellis Pharmaceuticals’s Book Value Per Share?
Book value per share is 1.96
Is Apellis Pharmaceuticals Cash Flow Positive?
-
What Is APLS Cash Flow From Operations?
Cash flow from operations (TTM) is -$637.6M -
What Is Apellis Pharmaceuticals’s Cash Flow From Financing?
Cash flow from financing (TTM) is $382.5M -
What Is Apellis Pharmaceuticals’s Cash Flow From Investing?
Cash flow from investing (TTM) is $123.5M
Apellis Pharmaceuticals Return On Invested Capital
-
Is Management Doing A Good Job?
APLS return on invested capital is -156.91% -
What Is Apellis Pharmaceuticals Return On Assets?
ROA measures how assets are converting to revenues and is -69.73% -
What Is APLS Return On Equity?
ROE is a measure of profitability and is -206.55%
Apellis Pharmaceuticals Earnings Date & Stock Price
-
What Is Apellis Pharmaceuticals's Stock Price Today?
A single share of APLS can be purchased today for 64.86 -
What Is Apellis Pharmaceuticals’s Stock Symbol?
Apellis Pharmaceuticals trades on the nasdaq under the ticker symbol: APLS -
When Is Apellis Pharmaceuticals’s Next Earnings Date?
The next quarterly earnings date for Apellis Pharmaceuticals is scheduled on February 21, 2024 -
When Is APLS's next ex-dividend date?
Apellis Pharmaceuticals's next ex-dividend date is December 6, 2023 -
How To Buy Apellis Pharmaceuticals Stock?
You can buy Apellis Pharmaceuticals shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Apellis Pharmaceuticals Competitors
-
Who Are Apellis Pharmaceuticals's Competitors?
Below is a list of companies who compete with Apellis Pharmaceuticals or are related in some way:
Apellis Pharmaceuticals Dividend Yield
Data Unavailable
Apellis Pharmaceuticals Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | -18.1% |
Revenue: | 400.54% | 11.45% |
Analyst Recommendations
Buy Recommendations: | 10 |
---|---|
Hold Recommendations: | 3 |
Sell Recommendations: | 0 |
Price Target: | 73.75 |
Upside from Last Price: | 13.71% |